The U.S. FDA has approved diazoxide choline for the treatment of hyperphagia in adult and pediatric patients aged four and older with Prader-Willi syndrome (PWS). Diazoxide choline reduces fasting plasma insulin levels and increases blood glucose levels by inhibiting insulin release from the pancreas.
Clinical evidence In a clinical trial conducted on 77 patients with hyperphagia and PWS, diazoxide choline significantly reduced hyperphagia over 16 weeks compared to a placebo (Hyperphagia Questionnaire for Clinical Trials Total score: 2.6 vs. 7.6). Dosage and administration Extended-release tablet Administered orally once daily Test fasting plasma glucose and HbA1c levels before initiation and optimize blood glucose in patients with hyperglycemia Contraindications Hypersensitivity to diazoxide, other components of diazoxide, or to thiazides Warnings and precautions Hyperglycemia Risk of…
